GSK begins large-scale study of diabetes drug Syncria

02/17/2009 | Reuters

GlaxoSmithKline is kicking off a large-scale Phase III trial of Syncria, an experimental diabetes drug that belongs to a class of treatments known as GLP-1 agonists. The drug is expected to compete with other incretin mimetics under development, including Novo Nordisk's liraglutide and Roche Holding's taspoglutide.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA